Table 1.
Characteristics of Discovery Stage Cohorts
| Cohort | N | Visits/ follow-up years |
Baseline | Long term average | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| Age, Years Mean (SD) |
BMI, kg/m2 Mean (SD) |
SBP, mmHg Mean (SD) |
DBP, mmHg Mean (SD) |
Anti-HTN Medication, % |
BMI, kg/m2 Mean (SD) |
SBP, mmHg Mean (SD) |
DBP, mmHg Mean (SD) |
|||
| DFTJ | 1,155 | 2/5 | 62.5 (7.7) | 24.8 (3.3) | 132.5 (20.4) | 79.7 (11.7) | 29.7 | 24.4 (3.3) | 146.7 (23.8) | 83.3 (12.8) |
| GenSalt | 1,767 | 3/8 | 39.0 (9.2) | 23.4 (3.1) | 117.0 (14.1) | 73.8 (10.2) | 0.4 | 24.2 (3.2) | 123.4 (15.0) | 78.6 (9.7) |
| KARE | 6,447 | 3/7 | 52.2 (8.8) | 24.6 (3.1) | 122.6 (19.3) | 80.9 (11.7) | 10.6 | 24.6 (3.0) | 120.0 (16.4) | 79.4 (9.7) |
| MESA (Chinese subjects) | 775 | 4/6 | 62.4 (10.4) | 24.0 (3.3) | 127.4 (23.7) | 73.3 (10.9) | 29.0 | 24.0 (3.2) | 126.8 (21.2) | 72.3 (9.6) |
| NHAPC | 2,004 | 2/6 | 58.2 (5.9) | 24.5 (3.6) | 139.6 (22.6) | 79.9 (10.8) | 26.4 | 24.6 (3.5) | 137.8 (18.8) | 80.3 (9.5) |
| SiMES | 1,494 | 2/6 | 57.2 (10.1) | 26.6 (4.8) | 148.0 (24.0) | 81.2 (11.3) | 29.4 | 26.7 (4.8) | 146.9 (19.9) | 80.3 (9.4) |
| SP2 | 2,177 | 2/10 | 38.2 (11.1) | 22.5 (3.5) | 118.8 (16.8) | 71.8 (11.8) | 5.2 | 22.9 (3.7) | 130.6 (21.2) | 77.6 (11.4) |
| TWT2D2 | 1,599 | 2/2 | 61.6 (11.8) | 33.2 (9.0) | 134.6 (16.7) | 80.8 (10.5) | 30.8 | 33.2 (9.0) | 135.1 (16.9) | 78.7 (11.2) |
| TUDR | 1,004 | 4/4 | 64.3 (11.9) | 24.8 (4.3) | 134.6 (17.7) | 75.8 (10.9) | 60.3 | - | 136.6 (20.7) | 76.8 (12.1) |
BMI=Body mass index; DBP=Diastolic blood pressure; DFTJ=Dong Feng Tongji Cohort Study; GenSalt=Genetic Epidemiology Network of Salt-Sensitivity; HTN=Hypertension; KARE=Korean Association Resource; MESA=Multi-Ethnic Study of Atherosclerosis; NHAPC=Nutrition and Health of Aging Population in China; SBP=Systolic blood pressure; SiMES=Singapore Malay Eye Study; SP2=Singapore Prospective Study Program; TUDR=Taiwan and US Diabetic Retinopathy Study; TWT2DS=Taiwan Type II Diabetes Study